Glomerular diseases: FSGS

Clinical Journal of the American Society of Nephrology

Volumn 9, Issue 3, 2014, Pages 626-632

  Bose, Bhadran ^a   Cattran, Daniel ^a  

^a UNIVERSITY HEALTH NETWORK   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

15 DEOXYSPERGUALIN; ADALIMUMAB; CYCLOSPORIN A; DEXAMETHASONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NEPHRIN; PIRFENIDONE; PODOCIN; RAPAMYCIN; RITUXIMAB;

ARTICLE; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE PREDISPOSITION; FOCAL GLOMERULOSCLEROSIS; GENE MUTATION; GENETIC ANALYSIS; HISTOLOGY; HUMAN; KIDNEY FUNCTION; OBESITY; PROGNOSIS; TREATMENT RESPONSE;

BIOPSY; GENETIC MARKERS; GLOMERULOSCLEROSIS, FOCAL SEGMENTAL; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY GLOMERULUS; PREDICTIVE VALUE OF TESTS; TREATMENT OUTCOME;

EID: 84896824829     PISSN: 15559041     EISSN: 1555905X     Source Type: Journal    
DOI: 10.2215/CJN.05810513     Document Type: Article

References (51)

1. Haas M, Meehan SM, Karrison TG, Spargo BH: Changing etiologies of unexplained adult nephrotic syndrome: A comparison of renal biopsy findings from 1976-1979 and 1995-1997. Am J Kidney Dis 30: 621-631, 1997.
2. Fuchshuber A, Gribouval O, Ronner V, Kroiss S, Karle S, Brandis M, Hildebrandt F: Clinical and genetic evaluation of familial steroid-responsive nephrotic syndrome in childhood. J Am Soc Nephrol 12: 374-378, 2001.
3. Hinkes B, Wiggins RC, Gbadegesin R, Vlangos CN, Seelow D, Nürnberg G, Garg P, Verma R, Chaib H, Hoskins BE, Ashraf S, Becker C, Hennies HC, Goyal M, Wharram BL, Schachter AD, Mudumana S, Drummond I, Kerjaschki D, Waldherr R, Dietrich A, Ozaltin F, Bakkaloglu A, Cleper R, Basel-Vanagaite L, Pohl M, Griebel M, Tsygin AN, Soylu A, Müller D, Sorli CS, Bunney TD, Katan M, Liu J, Attanasio M, O'toole JF, Hasselbacher K, Mucha B, Otto EA, Airik R, Kispert A, Kelley GG, Smrcka AV, Gudermann T, Holzman LB, Nürnberg P, Hildebrandt F: Positional cloning uncovers mutations in PLCE1 responsible for a nephrotic syndrome variant that may be reversible. Nat Genet 38: 1397-1405, 2006.
4. Kidney DiseaseImproving Global Outcomes (KDIGO) Glomerulonephritis Work Group: KDIGO Clinical Practice Guideline for Glomerulonephritis. Kidney Int Suppl 2: 139-274, 2012.
5. Korbet SM: Clinical picture and outcome of primary focal segmental glomerulosclerosis. NephrolDial Transplant 14[Suppl 3]: 68-73, 1999.
6. Kitiyakara C, Eggers P, Kopp JB: Twenty-one-year trend in ESRD due to focal segmental glomerulosclerosis in the United States. Am J Kidney Dis 44: 815-825, 2004.
7. D'Agati VD, Fogo AB, Bruijn JA, Jennette JC: Pathologic classification of focal segmental glomerulosclerosis: A working proposal. Am J Kidney Dis 43: 368-382, 2004.
8. Deegens JK, Steenbergen EJ, Borm GF, Wetzels JF: Pathological variants of focal segmental glomerulosclerosis in an adult Dutch population-epidemiology and outcome. Nephrol Dial Transplant 23: 186-192, 2008.
9. Stokes MB, Valeri AM, Markowitz GS, D'Agati VD: Cellular focal segmental glomerulosclerosis: Clinical and pathologic features. Kidney Int 70: 1783-1792, 2006.
10. Stokes MB, Markowitz GS, Lin J, Valeri AM, D'Agati VD: Glomerular tip lesion: A distinct entity within the minimal change disease/focal segmental glomerulosclerosis spectrum. Kidney Int 65: 1690-1702, 2004.
11. Barisoni L, Schnaper HW, Kopp JB: A proposed taxonomy for the podocytopathies: A reassessment of the primary nephrotic diseases. Clin J Am Soc Nephrol 2: 529-542, 2007.
12. Cattran D, Neogi T, Sharma R, McCarthy ET, Savin VJ: Serial estimates of serum permeability activity and clinical correlates in patients with native kidney focal segmental glomerulosclerosis. J Am Soc Nephrol 14: 448-453, 2003.
13. McCarthy ET, Sharma M, Savin VJ: Circulating permeability factors in idiopathic nephrotic syndrome and focal segmental glomerulosclerosis. Clin J Am Soc Nephrol 5: 2115-2121, 2010.
14. McCarthy ET, Sharma M, Sharma R, Falk RJ, Jennette JC: Sera from patients with collapsing focal segmental glomerulosclerosis increase albumin permeability of isolated glomeruli. J Lab Clin Med 143: 225-229, 2004.
15. Gladson CL, Cheresh DA: Glioblastoma expression of vitronectin and the alpha v beta 3 integrin. Adhesion mechanism for transformed glial cells. J Clin Invest 88: 1924-1932, 1991.
16. Wei C, El Hindi S, Li J, Fornoni A, Goes N, Sageshima J, Maiguel D, Karumanchi SA, Yap HK, Saleem M, Zhang Q, Nikolic B, Chaudhuri A, Daftarian P, Salido E, Torres A, Salifu M, Sarwal MM, Schaefer F, Morath C, Schwenger V, Zeier M, Gupta V, Roth D, Rastaldi MP, Burke G, Ruiz P, Reiser J: Circulating urokinase receptor as a cause of focal segmental glomerulosclerosis. Nat Med 17: 952-960, 2011.
17. Backes Y, van der Sluijs KF, Mackie DP, Tacke F, Koch A, Tenhunen JJ, Schultz MJ: Usefulness of suPAR as a biological marker in patients with systemic inflammation or infection: A systematic review. Intensive Care Med 38: 1418-1428, 2012.
18. Koch A, Voigt S, Kruschinski C, Sanson E, Dückers H, Horn A, Yagmur E, Zimmermann H, Trautwein C, Tacke F: Circulating soluble urokinase plasminogen activator receptor is stably elevated during the first week of treatment in the intensive care unit and predicts mortality in critically ill patients. Crit Care 15: R63, 2011.
19. Hinkes BG, Mucha B, Vlangos CN, Gbadegesin R, Liu J, Hasselbacher K, Hangan D, Ozaltin F, Zenker M, Hildebrandt F; Arbeitsgemeinschaft für Paediatrische Nephrologie Study Group: Nephrotic syndrome in the first year of life: Two thirds of cases are caused by mutations in 4 genes (NPHS1, NPHS2, WT1, and LAMB2). Pediatrics 119: e907-e919, 2007.
20. Putaala H, Soininen R, Kilpeläinen P, Wartiovaara J, Tryggvason K: The murine nephrin gene is specifically expressed in kidney, brain and pancreas: inactivation of the gene leads to massive proteinuria and neonatal death. Hum Mol Genet 10: 1-8, 2001.
21. Pereira AC, Pereira AB, Mota GF, Cunha RS, Herkenhoff FL, Pollak MR, Mill JG, Krieger JE: NPHS2 R229Q functional variant is associated with microalbuminuria in the general population. Kidney Int 65: 1026-1030, 2004.
22. Löwik M, Levtchenko E, Westra D, Groenen P, Steenbergen E, Weening J, Lilien M, Monnens L, van den Heuvel L: Bigenic heterozygosity and the development of steroid-resistant focal segmental glomerulosclerosis. Nephrol Dial Transplant 23: 3146-3151, 2008.
23. Winn MP, Conlon PJ, Lynn KL, Farrington MK, Creazzo T, Hawkins AF, Daskalakis N, Kwan SY, Ebersviller S, Burchette JL, Pericak-Vance MA, Howell DN, Vance JM, Rosenberg PB: A mutation in the TRPC6 cation channel causes familial focal segmental glomerulosclerosis. Science 308: 1801-1804, 2005.
24. Zenker M, Aigner T, Wendler O, Tralau T, Müntefering H, Fenski R, Pitz S, Schumacher V, Royer-Pokora B, Wühl E, Cochat P, Bouvier R, Kraus C, Mark K, Madlon H, Dötsch J, Rascher W, Maruniak-Chudek I, Lennert T, Neumann LM, Reis A: Human laminin beta2 deficiency causes congenital nephrosis with mesangial sclerosis and distinct eye abnormalities. Hum Mol Genet 13: 2625-2632, 2004.
25. Genovese G, Tonna SJ, Knob AU, Appel GB, Katz A, Bernhardy AJ, Needham AW, Lazarus R, Pollak MR: A risk allele for focal segmental glomerulosclerosis in African Americans is located within a region containingAPOL1andMYH9. Kidney Int 78: 698-704, 2010.
26. Genovese G, Friedman DJ, Ross MD, Lecordier L, Uzureau P, Freedman BI, Bowden DW, Langefeld CD, Oleksyk TK, Uscinski Knob AL, Bernhardy AJ, Hicks PJ, Nelson GW, Vanhollebeke B, Winkler CA, Kopp JB, Pays E, Pollak MR: Association of trypanolytic ApoL1 variantswith kidney disease in AfricanAmericans. Science 329: 841-845, 2010.
27. Lipkowitz MS, Freedman BI, Langefeld CD, Comeau ME, Bowden DW, Kao WH, Astor BC, Bottinger EP, Iyengar SK, Klotman PE, Freedman RG, Zhang W, Parekh RS, Choi MJ, Nelson GW, Winkler CA, Kopp JB; SK Investigators: Apolipoprotein L1 gene variants associate with hypertension-attributed nephropathy and the rate of kidney function decline in African Americans. Kidney Int 83: 114-120, 2013.
28. Fogo A, Breyer JA, Smith MC, Cleveland WH, Agodoa L, Kirk KA, Glassock R; AASK Pilot Study Investigators: Accuracy of the diagnosis of hypertensive nephrosclerosis in African Americans: A report fromthe AfricanAmerican Study of KidneyDisease (AASK) Trial. Kidney Int 51: 244-252, 1997.
29. Rood IM, Deegens JK, Wetzels JF: Genetic causes of focal segmental glomerulosclerosis: Implications for clinical practice. Nephrol Dial Transplant 27: 882-890, 2012.
30. Adelman RD, Restaino IG, Alon US, Blowey DL: Proteinuria and focal segmental glomerulosclerosis in severely obese adolescents. J Pediatr 138: 481-485, 2001.
31. Chen HM, Liu ZH, Zeng CH, Li SJ, Wang QW, Li LS: Podocyte lesions in patients with obesity-related glomerulopathy. Am J Kidney Dis 48: 772-779, 2006.
32. Kambham N, Markowitz GS, Valeri AM, Lin J, D'Agati VD: Obesity-related glomerulopathy: an emerging epidemic. Kidney Int 59: 1498-1509, 2001.
33. Juncos LA, Ito S: Disparate effects of insulin on isolated rabbit afferent and efferent arterioles. J Clin Invest 92: 1981-1985, 1993.
34. Verani RR: Obesity-associated focal segmental glomerulosclerosis: Pathological features of the lesion and relationship with cardiomegaly and hyperlipidemia. Am J Kidney Dis 20: 629- 634, 1992.
35. Wolf G, Hamann A, Han DC, Helmchen U, Thaiss F, Ziyadeh FN, Stahl RA: Leptin stimulates proliferation and TGF-beta expression in renal glomerular endothelial cells: potential role in glomerulosclerosis. Kidney Int 56: 860-872, 1999.
36. Troyanov S, Wall CA, Miller JA, Scholey JW, Cattran DC; Toronto Glomerulonephritis Registry Group: Focal and segmental glomerulosclerosis: Definition and relevance of a partial remission. J Am Soc Nephrol 16: 1061-1068, 2005.
37. Ordonez JD, Hiatt RA, Killebrew EJ, Fireman BH: The increased risk of coronary heart disease associated with nephrotic syndrome. Kidney Int 44: 638-642, 1993.
38. Abbate M, Zoja C, Remuzzi G: How does proteinuria cause progressive renal damage? J Am Soc Nephrol 17: 2974-2984, 2006.
39. Faul C, Donnelly M, Merscher-Gomez S, Chang YH, Franz S, Delfgaauw J, Chang JM, Choi HY, Campbell KN, Kim K, Reiser J, Mundel P: The actin cytoskeleton of kidney podocytes is a direct target of the antiproteinuric effect of cyclosporine A. NatMed 14: 931-938, 2008.
40. Fornoni A, Sageshima J, Wei C, Merscher-Gomez S, Aguillon- Prada R, Jauregui AN, Li J, Mattiazzi A, Ciancio G, Chen L, Zilleruelo G, Abitbol C, Chandar J, Seeherunvong W, Ricordi C, Ikehata M, Rastaldi MP, Reiser J, Burke GW 3rd: Rituximab targets podocytes in recurrent focal segmental glomerulosclerosis. Sci Transl Med 3: 85ra46, 2011.
41. Gipson DS, Trachtman H, Kaskel FJ, Greene TH, Radeva MK, Gassman JJ, Moxey-Mims MM, Hogg RJ, Watkins SL, Fine RN, Hogan SL, Middleton JP, Vehaskari VM, Flynn PA, Powell LM, Vento SM, McMahan JL, Siegel N, D'Agati VD, Friedman AL: Clinical trial of focal segmental glomerulosclerosis in children and young adults. Kidney Int 80: 868-878, 2011.
42. Fernandez-Fresnedo G, Segarra A, Gonzalez E, Alexandru S, Delgado R, Ramos N, Egido J, Praga M; Trabajo de Enfermedades Glomerulares de la Sociedad Espa~nola de Nefrologia (GLOSEN): Rituximab treatment of adult patients with steroid-resistant focal segmental glomerulosclerosis. Clin J Am Soc Nephrol 4: 1317-1323, 2009.
43. Savin VJ, McCarthy ET, Sharma R, Charba D, Sharma M: Galactose binds to focal segmental glomerulosclerosis permeability factor and inhibits its activity. Transl Res 151: 288-292, 2008.
44. Cho ME, Smith DC, Branton MH, Penzak SR, Kopp JB: Pirfenidone slows renal function decline in patients with focal segmental glomerulosclerosis. Clin J Am Soc Nephrol 2: 906-913, 2007.
45. Peyser A, Machardy N, Tarapore F, Machardy J, Powell L, Gipson DS, Savin V, Pan C, Kump T, Vento S, Trachtman H: Follow-up of phase I trial of adalimumab and rosiglitazone in FSGS: III. Report of the FONT study group. BMC Nephrol 11: 2, 2010.
46. Le Berre L, Bruneau S, Naulet J, Renaudin K, Buzelin F, Usal C, Smit H, Condamine T, Soulillou JP, Dantal J: Induction of T regulatory cells attenuates idiopathic nephrotic syndrome. J AmSoc Nephrol 20: 57-67, 2009.
47. Cho ME, Hurley JK, Kopp JB: Sirolimus therapy of focal segmental glomerulosclerosis is associated with nephrotoxicity. Am J Kidney Dis 49: 310-317, 2007.
48. Ramirez J, Carpio D, Mezzano S, Mukdsi J, Ardiles L: [Bariatric surgery in patients with focal segmental glomerulosclerosis secondary to obesity]. Nefrologia 29: 266-269, 2009.
49. Radhakrishnan J, Cattran DC: The KDIGO practice guideline on glomerulonephritis: Reading between the (guide)lines- application to the individual patient. Kidney Int 82: 840-856, 2012.
50. Wei C, Trachtman H, Li J, Dong C, Friedman AL, Gassman JJ, McMahan JL, Radeva M, Heil KM, Trautmann A, Anarat A, Emre S, Ghiggeri GM, Ozaltin F, Haffner D, Gipson DS, Kaskel F, Fischer DC, Schaefer F, Reiser J; PodoNet and FSGS CT Study Consortia: Circulating suPAR in two cohorts of primary FSGS. J Am Soc Nephrol 23: 2051-2059, 2012.
51. Huang J, Liu G, Zhang YM, Cui Z, Wang F, Liu XJ, Chu R, Chen Y, Zhao MH: Plasma soluble urokinase receptor levels are increased but do not distinguish primary from secondary focal segmental glomerulosclerosis. Kidney Int 84: 366-372, 2013